Psoriasis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Psoriasis is primarily an inflammatory skin condition characterized by reactive abnormal epidermal differentiation and hyperproliferation that affects 2-3% of the world's population. The pathophysiology of the disease is primarily characterized by the activation and migration of T-cells to the dermis, which results in the release of cytokines (tumor necrosis factor-alpha, TNF-alpha in particular) that cause inflammation and rapid skin cell production. It can cause many signs and symptoms, including dry, thick, and raised patches on the skin covered with a silvery-white coating called scale, and they can tend to itch. Itching can be especially severe in certain areas, such as the scalp, lower legs, and groin. When Psoriasis affects the hands and feet, painful fissures or cracks can form, requiring the use of one's hands and walking. Severe Psoriasis on the body can also create painful fissures and can bleed. It is considered the most prevalent autoimmune disease caused by inappropriate activation of the cellular immune system. T cells get activated, migrate to the dermis, and trigger the release of cytokines that cause inflammation and the rapid production of skin cells. It is not known what initiates the activation of the T cells. This initially pointed towards a significant role of T lymphocytes as inducers of the disease phenotype. The pathogenic contribution of this cell type has been investigated in several clinical studies involving more than a dozen immune-changing biological agents in Psoriasis patients.

The prevalence of Psoriasis varies from 2560 to 3250 cases per 100,000 populations in the USA, with a low diagnosis rate of ~49%.

 

The competitive landscape of Psoriasis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Psoriasis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Psoriasis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Psoriasis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Cedirogant        AbbVie  Phase 2

2          MP1032            MetrioPharm AG           Phase 2

3          Talarozole         Stiefel, a GSK Company            Phase 2

4          Bimekizumab    UCB Pharma    Phase 2

5          tapinarof           Dermavant Sciences, Inc.          Phase 3

6          Apremilast (CC-10004)  Amgen  Phase 3

7          M1095 (Sonelokimab)    Avillion LLP       Phase 2

8          DUR-928          Durect  Phase 2

9          LEO 80185 gel  LEO Pharma     Phase 3

10        IDP-118            Dow Pharmaceutical Sciences   Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more